Literature DB >> 17487406

Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.

Teppei Sonoda1, Kazunobu Sugimura, Shin-Ichi Ikemoto, Hidenori Kawashima, Tatsuya Nakatani.   

Abstract

Although intravesical instillation of bacillus Calmette-Guerin (BCG) is a clinically well-recognized therapy for bladder carcinoma in situ and recurrence prophylaxis, these mechanisms have not been fully understood. We studied the effects of BCG infection (Connaught strain) on target cancer cells and host immune systems in murine bladder cancer. The bladder cancer cell line, MB49, was used in C57/BL6 mice in vivo and in vitro. In vitro cytotoxicities against the cancer cell line were measured by 24-h 51Cr release assay. For effector cells, spleen mononuclear cells were obtained from mice injected intraperitoneally with BCG or BCG-infected irradiated MB49 cells. Although BCG infection of cancer cells did not affect the proliferation speed in vitro, the mice injected subcutaneously with BCG-infected MB49 cells survived significantly longer than those given untreated cancer cells. The mice surviving without tumor growth after injection of BCG-infected cancer cells could not reject a second injection of intact MB49 cells. In vitro cytotoxicity was enhanced by BCG infection of target cancer cells, but not by immunizing the mice with BCG from which effector cells were obtained. Moreover, cytotoxicity disappeared by depleting natural killer (NK) cells from effector cells. Although in vitro cytotoxicity was increased by immunizing the mice with BCG-infected irradiated MB49 cells, survival did not improve in these mice. These results suggest that a major part of BCG's anti-tumor effects can be attributed to the elimination of BCG-infected cancer cells by NK cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487406

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  Immune checkpoint inhibitors: a new frontier in bladder cancer.

Authors:  Max Kates; Nikolai A Sopko; Hotaka Matsui; Charles G Drake; Noah M Hahn; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2015-10-20       Impact factor: 4.226

Review 2.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

Review 3.  Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Authors:  Dongkui Song; Thomas Powles; Lei Shi; Lirong Zhang; Molly A Ingersoll; Yong-Jie Lu
Journal:  J Pathol       Date:  2019-06-24       Impact factor: 7.996

4.  A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer.

Authors:  Yuhan Sun; Alexander James Sedgwick; Md Abdullah-Al-Kamran Khan; Yaseelan Palarasah; Stefano Mangiola; Alexander David Barrow
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

Review 5.  BCG in Bladder Cancer Immunotherapy.

Authors:  Song Jiang; Gil Redelman-Sidi
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

6.  Autologous tumor cells/bacillus Calmette-Guérin/formalin-based novel breast cancer vaccine induces an immune antitumor response.

Authors:  María José Godoy-Calderón; Víctor Salazar; Eglys González-Marcano; Ana Federica Convit
Journal:  Oncotarget       Date:  2018-04-17

7.  Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.

Authors:  Takayuki Yoshino; Jun Miyazaki; Takahiro Kojima; Shuya Kandori; Masanobu Shiga; Takashi Kawahara; Tomokazu Kimura; Takashi Naka; Hideyasu Kiyohara; Miyuki Watanabe; Sho Yamasaki; Hideyuki Akaza; Ikuya Yano; Hiroyuki Nishiyama
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240

8.  BCG immunotherapy inhibits cancer progression by promoting the M1 macrophage differentiation of THP‑1 cells via the Rb/E2F1 pathway in cervical carcinoma.

Authors:  Limin Liu; Wenjuan Shi; Xiao Xiao; Xuemei Wu; Haiyan Hu; Shixin Yuan; Kai Liu; Zhihua Liu
Journal:  Oncol Rep       Date:  2021-09-28       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.